Chester County News and Community Website
WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has initiated an immediate review of clinical trials involving the international transfer of Americans’ living cells for genetic engineering and subsequent …
FDA Investigates Clinical Trials Sending U.S. DNA Overseas Read More
WILMINGTON, DE — ChristianaCare’s Gene Editing Institute has secured a prominent place on The Scientist’s Top 10 Innovations list for 2024, with its CRISPR in a Box™ teaching toolkit ranked …
Revolutionizing Science Education! ‘CRISPR in a Box’ Empowers Students and Earns Global Acclaim! Read More
WEST CHESTER, PA — Pathways Neuro Pharma, Inc. has announced a strategic partnership with Dragonfly 44 Capital, a move set to bolster the company’s financial and strategic capabilities. The agreement, …
Pathways Neuro Pharma Engages Dragonfly 44 Capital as Strategic Advisor Read More
PHILADELPHIA PA — Greater Philadelphia has emerged as a powerhouse in the cell and gene therapy industry, housing almost 10 percent of the world’s companies in this rapidly expanding sector. …
Greater Philadelphia Dominates Cell and Gene Therapy Landscape – A Beacon of Innovation and Employment Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has reached a significant milestone in the development of a groundbreaking treatment for geographic atrophy (GA), an advanced form of dry age-related macular …
Ocugen Advances in Revolutionary Gene Therapy for Age-Related Macular Degeneration Read More
MALVERN, PA — In a significant advancement for retinitis pigmentosa (RP) treatment, Ocugen, Inc. (NASDAQ: OCGN) has received favorable scientific advice from the European Medicines Agency (EMA) regarding its pivotal …
Ocugen’s Gene Therapy OCU400 Moves Closer to European Market with EMA’s Positive Opinion Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focusing on discovering, developing, and commercializing transformative therapies to cure blindness diseases, announced a significant milestone in its Phase 1/2 …
Ocugen Advances in Pioneering Gene Therapy for Geographic Atrophy with DSMB Approval to Proceed to Medium Dose in Clinical Trial Read More
PHILADELPHIA, PA — A paramount scientific breakthrough has been achieved by the combined intellectual prowess of researchers from the University of Pennsylvania (Penn), J. Craig Venter Institute (JCVI), and the …
Constructing the Path to Brave New Biotech: Single-copy Human Artificial Chromosomes Read More MALVERN, PA — Biopharmaceutical company Ocugen, Inc. (NASDAQ: OCGN) has announced the commencement of its Phase 1/2 GARDian clinical trial for OCU410ST (AAV5-hRORA), a gene therapy candidate being developed to …
Ocugen Initiates Phase 1/2 GARDian Clinical Trial for Stargardt Disease Therapy Read More
GMOs, or genetically modified organisms, are a hot topic in the news lately. But what are they, and why should you care? In this article, we will explain what GMOs …
GMOs: What They Are and What You Need to Know Read More